Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
LAVA Therapeutics N.V. - SIC # 2830 -
Ticker
Exchange
SIC #
Website
Latest Ticker
LVTX
Nasdaq
2830
www.lavatherapeutics.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for LAVA Therapeutics N.V.
LAVA Doses First Patient in Phase 1 LAVA-1266 Study in Hematological Cancers
- Jan 10th, 2025 1:23 pm
LAVA Reports Third Quarter 2024 Financial Results and Announces Pipeline Reprioritization and Cash Runway Extension into 2027
- Dec 10th, 2024 12:30 pm
LAVA Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
- Sep 3rd, 2024 12:00 pm
LAVA Reports Second Quarter 2024 Financial Results and Business Update
- Aug 20th, 2024 11:30 am
LAVA Therapeutics to Participate in the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference
- Jun 20th, 2024 11:30 am
LAVA Announces Annual Meeting of Shareholders
- Jun 10th, 2024 11:00 am
LAVA Therapeutics to Participate in the Jefferies Global Healthcare Conference
- May 30th, 2024 11:00 am
LAVA Provides Business Updates and Reports First Quarter 2024 Financial Results
- May 21st, 2024 11:00 am
LAVA Therapeutics to Participate in the Citizens JMP Life Sciences Conference
- May 6th, 2024 8:05 pm
LAVA Therapeutics Full Year 2023 Earnings: Revenues Disappoint
- Mar 21st, 2024 10:19 am
LAVA Provides Business Updates and Reports Fourth Quarter and Year-End Financial Results
- Mar 20th, 2024 11:00 am
LAVA Announces Clinical Development Milestone Achieved by PfizerĀ for PF-08046052 (formerly SGN-EGFRd2/LAVA-1223)
- Mar 5th, 2024 12:30 pm
Scroll